A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.

van Veggel, Bianca A M H; van der Wekken, Anthonie J; Paats, Marthe S; Hendriks, Lizza E L; Hashemi, Sayed M S; Daletzakis, Antonios; van den Broek, Daan; Bosch, Linda J W; Monkhorst, Kim; Smit, Egbert F; de Langen, Adrianus J

van Veggel, Bianca A M H; van der Wekken, Anthonie J; Paats, Marthe S; Hendriks, Lizza E L; Hashemi, Sayed M S; Daletzakis, Antonios; van den Broek, Daan; Bosch, Linda J W; Monkhorst, Kim; Smit, Egbert F; de Langen, Adrianus J.

Affiliation

van Veggel BAMH; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
Paats MS; Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
Hendriks LEL; Department of Pulmonary Diseases, Maastricht University Medical Center, Maastricht, the Netherlands.
Hashemi SMS; Department of Pulmonary Medicine, Amsterdam University Medical Centers, Vrije Universiteit Medical Center, and Cancer Center Amsterdam, Amsterdam, the Netherlands.
Daletzakis A; Department of Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Bosch LJW; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Monkhorst K; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
de Langen AJ; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Cancer ; 130(5): 683-691, 2024 03 01.

Article in En | MEDLINE | ID: mdl-37905752

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Humans; Female; Adult; Middle Aged; Aged; Aged, 80 and over; Male; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/pathology; Afatinib/therapeutic use; Cetuximab/adverse effects; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Lung Neoplasms/pathology; ErbB Receptors/genetics; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Exons; Mutation; Protein Kinase Inhibitors/adverse effects

Key words

EGFR exon 20 insertion; afatinib; cetuximab; non-small cell lung cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2024 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google